Key Client Fiduciary Advisors LLC Has $1.04 Million Holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX)

Key Client Fiduciary Advisors LLC grew its position in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 12.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 361,253 shares of the company’s stock after purchasing an additional 39,330 shares during the period. Key Client Fiduciary Advisors LLC’s holdings in Leap Therapeutics were worth $1,039,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Valence8 US LP purchased a new stake in shares of Leap Therapeutics in the 3rd quarter valued at approximately $48,000. HighTower Advisors LLC purchased a new position in Leap Therapeutics during the 3rd quarter worth approximately $65,000. HB Wealth Management LLC raised its stake in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after purchasing an additional 26,150 shares during the period. Marshall Wace LLP lifted its holdings in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new stake in shares of Leap Therapeutics in the third quarter worth $264,000. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Leap Therapeutics Stock Performance

Shares of LPTX opened at $2.20 on Friday. The company has a market capitalization of $84.30 million, a PE ratio of -1.14 and a beta of 0.17. The company’s 50 day moving average price is $2.93 and its 200 day moving average price is $2.77. Leap Therapeutics, Inc. has a 52 week low of $1.68 and a 52 week high of $4.79.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $5.50 price objective on shares of Leap Therapeutics in a research note on Thursday, January 16th.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.